Showing 6381-6390 of 7113 results for "".
- Sun Pharma to Present Data from Tildrakizumab Clinical Development Program at 2017 AAD Meetinghttps://practicaldermatology.com/news/sun-pharma-to-present-data-from-tildrakizumab-clinical-development-program-at-2017-aad-meeting/2458266/Sun Pharmaceutical Industries Ltd will present several new analyses from Phase-1 and the pivotal Phase-3 clinical trials (reSURFACE 1 and 2) of tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate-to-severe plaque psoriasis, at the 2017 Annual America
- Skin Diseases Remain Major Cause of Disabilityhttps://practicaldermatology.com/news/skin-diseases-remain-major-cause-of-disability/2458267/Skin diseases are the fourth leading cause of disability worldwide, according to the Global Burden of Disease 2013 Study which appears online in JAMA Dermatology. For the study, researchers estimate
- AAD Launches SkinSerious Campaignhttps://practicaldermatology.com/news/aad-launches-skinserious-campaign/2458268/The American Academy of Dermatology is launching a new campaign to raise awareness of the breadth of serious skin diseases as well as the critical role dermatologists play in an era of team-based health care. The SkinSerious campaign will launc
- Obagi Medical Products Collaborates with Suzan Obagi, MD and Nextcell Medical to Introduce New Linehttps://practicaldermatology.com/news/obagi-medical-products-collaborates-with-suzan-obagi-md-and-nextcell-medical-to-introduce-new-line/2458274/Valeant Pharmaceuticals International, Inc.’s wholly owned subsidiary Obagi Medical Products collaborated with Nextcell Medical Company to claim exclusive distribution of Suzan Obagi, MD’s line of skin care products throughout the United States. Established in 2013 with cosmetic
- Cloudy With a Chance of Wrinkles: Most Americans Fail to Protect Skin From Pollutionhttps://practicaldermatology.com/news/cloudy-with-a-chance-of-wrinkles-most-americans-fail-to-protect-skin-from-pollution/2458275/Most Americans don’t protect their skin from pollutants even though they are aware of the harm that pollution and other environmental stressors can cause to skin, according to a new survey by H2O+ Beauty. Just 33 percent of people purchase
- CareCredit to Acquire CitiHealth Card Portfoliohttps://practicaldermatology.com/news/carecredit/2458277/CareCredit has signed an agreement with Citibank, N.A. to acquire the Citi Health Card portfolio, further expanding its healthcare acceptance network in the United States. The portfolio acquisition includes more than 14,500 providers,
- Vision Medical's SmartGraft Now Offers Articulating Arm With Mayo Trayhttps://practicaldermatology.com/news/vision-medicals-smartgraft-now-offers-articulating-arm-with-mayo-tray/2458276/SmartGraft® Hair Restoration is rolling out its first articulating arm and mayo tray, Vision Medical Inc., reports. Available in February, the SmartGraft AMT (articulating mayo tray) provides ergonomic design for physicians Available to ne
- Researchers Discover New Antibiotic That May Fight MRSAhttps://practicaldermatology.com/news/researchers-discover-new-antibiotic-that-may-fight-mrsa/2458282/Researchers at the University of East Anglia (UEA) and the John Innes Centre (JIC) have uncovered a new antibiotic that they say is potent against antibiotic-resistant ‘superbugs’ like methicillin resistant Staphylococcus aureus (MRSA). The researchers isolated
- Ray Canole is New Chief Commercial Officer at Revision Skincarehttps://practicaldermatology.com/news/ray-canole-is-new-chief-commercial-officer-at-revision-skincare/2458287/Revision Skincare has announced the appointment of Ray Canole to the position of Chief Commercial Officer. He has over 15 years of business development and commercial related experience in dermatology-focused organizations and joins Revision from Renaissance Pharma, where he helped
- Rumor Has It Syneron Is Next In Week of Surprising Aquisitionshttps://practicaldermatology.com/news/rumor-has-it-syneron-is-next-in-week-of-surprising-aquisitions/2458286/Hot off the heels of Allergan’s acquisition of Zeltiq and Hologic Inc,’s surprising purchase of Cynosure Inc., media reports are now swirling that British private equity fund Apax Partners is looking to buy Syneron Medical for $350-$400 million. According to Israeli finan